Rhythm Pharmaceuticals
Tracked across 3 events · 19 articles · First seen Feb 14, 2026 · Last active May 28, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Impact: Rhythm Pharmaceuticals is the defendant in a class action lawsuit, accused of making false and misleading statements regarding its CELLECTRA device and INO-3107 Biologics License Application.
Apr 01, 2026 · 7 articles
Business
Rhythm Pharmaceuticals announced that the International — European Commission has expanded the marketing authorization for Setmelanotide (setmelanotide) to treat acquired hypothalamic obesity in adults and children aged 4 years and older. This authorization follows the…
Impact: Rhythm Pharmaceuticals announced the International — European Commission's expanded marketing authorization for Setmelanotide (setmelanotide) for acquired hypothalamic obesity, and presented positive long-term data at Pediatric Endocrine Society Annual Meeting, which is expected to boost its market position and revenue.
May 01, 2026 · 6 articles
95
International — European Commission expanded marketing authorization Rhythm PharmaceuticalsIMCIVREE EU Approval, Positive Data
85
Rhythm Pharmaceuticals announced new data Pediatric Endocrine SocietyIMCIVREE EU Approval, Positive Data
70
United States — Food and Drug Administration approved supplemental New Drug Application Rhythm PharmaceuticalsIMCIVREE EU Approval, Positive Data
NEWSDESK
Track Rhythm Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard